Key result
Nesiritide improves hemodynamics and provides a significant survival benefit compared to dobutamine or milrinone in patients with acute decompensated heart failure, though prolonged infusions may worsen renal function.
Why the study?
Does intravenous nesiritide improve hemodynamics and symptoms in patients with acute decompensated heart failure?
Does intravenous nesiritide improve hemodynamics and symptoms in patients with acute decompensated heart failure?
Nesiritide is a valuable vasodilator for the initial treatment of acute decompensated heart failure, offering hemodynamic and symptomatic benefits with a better mortality profile than positive inotropic agents.
May support short-term nesiritide for hemodynamics in acute decompensated heart failure; leaves open renal and survival effects pending randomized data.
Acute decompensated heart failure is a major health problem that is associated with several million hospitalizations worldwide each year. [1] In such patients, the predominant symptoms are dyspnea and fatigue which are associated with pulmonary venous congestion and low cardiac output. [2, 3] The primary goal of therapy is the rapid relief of these symptoms. Nesiritide, an intravenous (IV) form of human B-type natriuretic peptide is the first in a new pharmacologicclass of drug for treatment of decompensated congestive heart failure (CHF). Nesiritide, a recombinant B -type natriuretic peptide (BNP) with vasodilatory properties, [4] Nesiritide is also well established as an agent for improving hemo dynamics in patients with acute heart failure. Compared with other agents used in treatment of acute decompensated heart failure (ADHF), nesiritide is considered to be safer than inotropic agents such as dobutamine and milrinone. The ove all effects of nesiritide in patients associated with acute decompensated heart failure is reviewed.
No takes yet. Share an insight, caveat, or question.
S Rohini (2016) conducted a review in Acute Decompensated Heart Failure. Nesiritide vs. Dobutamine, milrinone, or nitroglycerin was evaluated. Nesiritide improves hemodynamics and provides a significant survival benefit compared to dobutamine or milrinone in patients with acute decompensated heart failure, though prolonged infusions may worsen renal function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: